A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
To compare the progression free survival of LY2510924 plus sunitinib therapy versus sunitinib
in the first-line setting for patients with metastatic clear-cell renal cell carcinoma.